Range Low Price High Price Comment
30 days $0.553 $1.10 Wednesday, 1st May 2024 BLRX stock ended at $0.672. This is 0.403% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 7.45% from a day low at $0.651 to a day high of $0.700.
90 days $0.553 $1.44
52 weeks $0.553 $2.53

Historical BioLineRx Ltd. prices

Date Open High Low Close Volume
Feb 03, 2016 $1.04 $1.04 $0.98 $1.01 45 300
Feb 02, 2016 $0.98 $1.01 $0.98 $0.99 48 300
Feb 01, 2016 $0.99 $1.02 $0.97 $1.00 18 900
Jan 29, 2016 $1.01 $1.04 $0.97 $1.03 96 600
Jan 28, 2016 $1.04 $1.04 $0.94 $1.00 74 900
Jan 27, 2016 $1.07 $1.08 $1.03 $1.06 52 600
Jan 26, 2016 $1.06 $1.10 $0.98 $1.09 88 000
Jan 25, 2016 $1.01 $1.08 $1.01 $1.05 134 900
Jan 22, 2016 $0.96 $1.05 $0.95 $1.03 117 000
Jan 21, 2016 $0.99 $0.99 $0.90 $0.96 81 800
Jan 20, 2016 $0.88 $0.94 $0.85 $0.94 239 000
Jan 19, 2016 $0.94 $1.04 $0.90 $0.95 225 100
Jan 15, 2016 $1.01 $1.01 $0.89 $0.96 261 200
Jan 14, 2016 $1.04 $1.05 $0.99 $1.01 220 600
Jan 13, 2016 $1.10 $1.11 $1.00 $1.06 454 700
Jan 12, 2016 $1.20 $1.27 $1.02 $1.09 1 817 100
Jan 11, 2016 $1.13 $1.17 $1.02 $1.03 387 700
Jan 08, 2016 $1.11 $1.17 $1.06 $1.12 289 800
Jan 07, 2016 $1.16 $1.18 $1.10 $1.10 243 200
Jan 06, 2016 $1.23 $1.23 $1.18 $1.18 185 000
Jan 05, 2016 $1.29 $1.29 $1.23 $1.23 158 300
Click to get the best stock tips daily for free!

About BioLineRx Ltd.

BioLineRx Ltd. BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in pat... BLRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT